論文

2012年4月

Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma.

Journal of gastroenterology
  • Hideaki Kinugasa
  • Kazuhiro Nouso
  • Yasuto Takeuchi
  • Tetsuya Yasunaka
  • Hideki Onishi
  • Shin-ichiro Nakamura
  • Hidenori Shiraha
  • Kenji Kuwaki
  • Hiroaki Hagihara
  • Fusao Ikeda
  • Yasuhiro Miyake
  • Akinobu Takaki
  • Kazuhide Yamamoto
  • 全て表示

47
4
開始ページ
421
終了ページ
6
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1007/s00535-011-0492-9

BACKGROUND: Radiofrequency ablation (RFA) is a standard therapy for the treatment of hepatocellular carcinoma (HCC) with 3 or fewer tumors of up to 3 cm (early-stage HCC); when RFA is unsuccessful or unfeasible, transcatheter arterial chemoembolization (TACE) has often been performed. However, little information about the outcome of TACE for early-stage HCC has been reported and it is hard to decide whether to perform additional treatment following TACE in these difficult conditions. The aim of this study was to determine the risk factors for local or intrahepatic distant recurrence after TACE in early-stage HCC. METHODS: Among 1,560 newly diagnosed HCC patients who were admitted to Okayama University Hospital, 43 patients with early-stage HCC who received only TACE in at least one nodule were enrolled in this study. We analyzed the risk factors for local and distant recurrence by the Cox proportional hazard model. RESULTS: The local recurrence rates and intrahepatic distant recurrence rates at 3 months, 6 months, and 1 year were 18.6, 33.4, and 61.8%, and 2.8, 2.8, and 34.3%, [corrected] respectively.Among 12 parameters examined as possible risk factors for recurrence, heterogeneous Lipiodol uptake (risk ratio 3.38; 95% confidence interval 1.14-10.60) and high serum des-gamma-carboxy prothrombin (DCP) (2.58; 1.03-7.14) were significantly correlated with local recurrence, and the presence of multiple tumors (10.64; 1.76-93.75) was significantly correlated with intrahepatic distant recurrence. CONCLUSIONS: Heterogeneous Lipiodol uptake, high serum DCP, and multiple tumors are risk factors for recurrence in patients with early-stage HCC who have undergone palliative TACE.

リンク情報
DOI
https://doi.org/10.1007/s00535-011-0492-9
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/22048256
ID情報
  • DOI : 10.1007/s00535-011-0492-9
  • PubMed ID : 22048256

エクスポート
BibTeX RIS